Trial Profile
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2014 New trial record